This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RTL1000

Artielle ImmunoTherapeutics, Inc.

Drug Names(s): RTL 1000

Description: RTL1000 is a novel protein drug with a highly-selective mechanism of action that targets pathogenic T-cells responsible for triggering and sustaining multiple sclerosis. RTL1000 disrupts the activation of the T cells, preventing the release of the inflammatory cytokines and causing the release of anti-inflammatory cytokines.

RTL1000 consists of the alpha1and beta1 domains of DR2 linked to the encephalitogenic MOG-35-55 peptide (VG312). Thus, RTL100 is designed to induce T cell tolerance to the MOG peptide thought to be associated with activated T cells in patients with multiple sclerosis.


RTL1000 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug